Successful use of hepatitis B surface antigen–positive liver grafts in recipients with hepatitis B virus–related liver diseases

Li Jiang,Lunan Yan,Bo Li,T. Wen,Jichun Zhao,Lisheng Jiang,Jiayin Yang,Mingqing Xu,Wentao Wang

DOI: https://doi.org/10.1002/lt.22379

2011-10-01

Liver Transplantation

Abstract:The worldwide discrepancy between the availability of suitable liver donors and the need for liver transplantation (LT) has forced many centers to accept socalled marginal grafts that previously might have been discarded. In this extended pool, liver grafts from hepatitis B surface antigen (HBsAg)–positive donors without significant liver disease may be suitable only for hepatitis B virus (HBV)–infected patients in the absence of ideal donor organs: these grafts inevitably lead to HBV reactivation or de novo hepatitis in the absence of immunoprophylaxis. However, the experience with the transplantation of these grafts into HBsAg-positive recipients is extremely limited, and the number of patients involved in these studies (mostly single case reports) is too small for firm conclusions to be drawn. The prevalence of HBV in the general Chinese population is very high (the HBsAg-positive rate is approximately 10%), and a considerable number of potential donors are inactive HBV carriers without significant liver disease. In this study, we report our experience with the transplantation of liver grafts from HBsAgpositive donors into 6 HBV recipients; our goal is to evaluate more carefully whether posttransplant outcomes are affected when HBsAg-positive donor livers are matched to HBsAg-positive recipients. Six patients with HBV-related end-stage liver disease received liver grafts from HBsAg-positive donors; they provided informed consent after they were warned about the potential for a poor prognosis and the increased risks for living donors. All procedures were approved by the West China Hospital Ethics Committee, and in accordance with the ethical guidelines of the Declaration of Helsinki. The initial hepatitis B prophylaxis regimen and the immunosuppression protocol adopted by our center have been described previously. The clinical characteristics of the 6 recipients are summarized in Supporting Table 1. There was no evidence of a coinfection with hepatitis C virus, hepatitis D virus, or human immunodeficiency virus in any of the patients, and no patient was confirmed to have developed tyrosine-methionine-aspartate-aspartate mutants at the time of LT. The mean length of the hospital stay after LT was 30.2 6 17.6 days (range 1⁄4 15-64 days). All recipients except recipient 3 recovered promptly after LT and experienced a quick normalization of their liver enzyme levels and blood coagulation function. Because of the severity of recipient 3’s disease, his liver enzyme levels, blood coagulation function, and serum creatinine level normalized 2 months, 1 week, and 38 days after transplantation, respectively. Unfortunately, all the patients still remained HBsAg-positive after LT. Their titers for the antibody to HBsAg were not increased to 100 IU/L even with 1200 IU of hepatitis B immunoglobulin (HBIG) every 2 weeks. Hence, HBIG was discontinued after LT (mean 1⁄4 6 6 1.9 months, range 1⁄4 3-8 months), and the initial prophylaxis protocol was replaced with a therapy combining lamivudine and adefovir. Serum HBV DNA became undetectable in recipients 1, 2, and 3 in postoperative months 2, 1, and 3, respectively, and it remained undetectable. Recipients 4, 5, and 6 were always HBV DNA–negative. During a mean follow-up of 22.5 6 19.3 months (range 1⁄4 5-60 months), all 6 recipients remained alive and showed no evidence of a hepatitis flare-up or lamivudine or adefovir resistance, and 4 recipients with hepatocellular carcinoma showed no signs of tumor recurrence. During the follow-up, recipients 1, 2, and 4 each suffered 1 episode of liver function deterioration, and the remaining patients continued to have stable liver function profiles. The deterioration of recipient 1’s liver function occurred in posttransplant month 13. A liver biopsy sample demonstrated acute allograft rejection and a chronic HBV infection, but there was no evidence of a hepatitis flare-up [the presence of

Medicine